^
Chr del(17)(p13.1)
|
CLL
|
Chr del(17)(p13.1)
|
CLL
|
ibrutinib Sensitive: B - Late Trials
|
ibrutinib Sensitive: B - Late Trials
|
Chr del(17)(p13.1)
|
CLL
|
Chr del(17)(p13.1)
|
CLL
|
rituximab + ibrutinib Sensitive: B - Late Trials
|
rituximab + ibrutinib Sensitive: B - Late Trials
|
Chr del(17)(p13.1)
|
CLL
|
Chr del(17)(p13.1)
|
CLL
|
acalabrutinib Sensitive: B - Late Trials
|
acalabrutinib Sensitive: B - Late Trials
|
Chr del(17)(p13.1)
|
CLL
|
Chr del(17)(p13.1)
|
CLL
|
alemtuzumab Sensitive: C3 – Early Trials
|
alemtuzumab Sensitive: C3 – Early Trials
|
Chr del(17)(p13.1)
|
CLL
|
Chr del(17)(p13.1)
|
CLL
|
obinutuzumab Sensitive: C3 – Early Trials
|
obinutuzumab Sensitive: C3 – Early Trials
|
Chr del(17)(p13.1)
|
Small Lymphocytic Lymphoma
|
Chr del(17)(p13.1)
|
Small Lymphocytic Lymphoma
|
acalabrutinib Sensitive: C3 – Early Trials
|
acalabrutinib Sensitive: C3 – Early Trials
|
